Anatara Lifesciences Ltd (AU:ANR) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences is advancing its Phase II trial for GaRP in treating Irritable Bowel Syndrome and has introduced a new anti-obesity project aimed at creating an oral medication for weight management. The company has successfully raised capital through a placement to sophisticated investors, demonstrating its commitment to enhancing shareholder value and expanding its human health portfolio.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.